RegenCell BioScience Holdings (RGC)

[shinhari1309]

Regencell (RGC) was top performing IPO Stock in 2021 with 237% return above its IPO price of $9.50

The year 2021 was the busiest year for deals since 2000, with over a thousand (1035 nos) listed companies in the United States. Biotech and Healthcare sectors took an overwhelming portion of 36% of the total IPO listed.

While it is not the strategy for most investors to target IPO shares, it is a surprise that the top performing IPO counter is a company with does not turn heads when mentioned. (ie. not a household name or famous company).

Regencell Bioscience (NASDAQ:RGC). RGC is the top performing stock of all 2021 IPOs according to [stockanalysis.com/ipos/2021/](http://stockanalysis.com/ipos/2021/). As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.

An article published in June 2022 has covered that RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.

Some key foundation points from the company,
As mentioned above, RGC is closely held by the CEO who owns over 81% of the company. He has used $5.9 million of his personal funds to purchase RGC shares from the open market since its IPO.

His consistent share purchases convey his confidence, commitment and conviction in the company and is putting his money where his mouth is. There are few companies that have the CEO owning this much of the business. The company’s entire management team has also extended the lock-up period of their share options, which shows they are collectively committed to their goal and mission, which is to save and improve lives.

(https://www.benzinga.com/amp/content/28316977)